Results 281 to 290 of about 296,469 (371)

Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study. [PDF]

BMC Infect Dis
Lopes SS, Pericot-Valverde I, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Karasz A, Arnsten J, Moschella P, Heo M, Litwin AH.   +16 more
europepmc   +1 more source

The effects of sustained virological response to direct‐acting anti‐viral therapy on the risk of extrahepatic manifestations of hepatitis C infection

, 2019
Hashem B. El‐Serag, Israel C. Christie, Amy Puenpatom, Diana Castillo, Fasiha Kanwal, Jennifer R. Kramer   +5 more
openalex   +2 more sources

Expert opinions regarding the concept of blue carbon in seaweed systems

Phycological Research, EarlyView.
SUMMARY A collection of expert opinions critically evaluates the role of seaweed in blue carbon strategies for climate change mitigation. While the concept of fast‐growing seaweed to capture atmospheric carbon is appealing, the experts largely agree that its potential for direct, long‐term carbon sequestration is currently overstated and faces ...
Gregory N. Nishihara, Yoichi Sato, Aaron M. Eger, John Barry Gallagher, Catriona Hurd, Hiroshi Kawai, Tomohiro Kuwae, Albert Pessarrodona   +7 more
wiley   +1 more source

Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China. [PDF]

BMC Infect Dis
Huang R, Shang J, Chen H, Li J, Xie Q, Feng J, Wei L, Rao H.   +7 more
europepmc   +1 more source

Long‐term outcome of chronic hepatitis C after sustained virological response to interferon‐based therapy

, 2013
Christopher Koh, Theo Heller, Vanessa Haynes–Williams, Koji Hara, Xiongce Zhao, Jordan J. Feld, David E. Kleiner, Yaron Rotman, Marc G. Ghany, T. Jake Liang, Jay H. Hoofnagle   +10 more
openalex   +1 more source

Pan‐European Fragile Populations Cohort for COVID‐19: What Worked, What Didn't, and Lessons Learned

Transplant Infectious Disease, EarlyView.
ABSTRACT The COVID‐19 pandemic exposed the vulnerability of immunocompromised hosts and the scarcity of evidence guiding their management. Within the European Horizon 2020 ORCHESTRA project, a multinational consortium connected existing and new cohorts to harmonize data, laboratory methods, and clinical expertise across fragile populations. The fragile
Beatrice Tazza, Cecilia Bonazzetti, Natascia Caroccia, Michela Di Chiara, Lorenzo Maria Canziani, Anna Maria Azzini, Zaira R. Palacios Baena, Paula Olivares‐Navarro, Jesús Rodríguez‐Baño, Evelina Tacconelli, Pierluigi Viale, Maddalena Giannella   +11 more
wiley   +1 more source

VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response. [PDF]

J Med Ultrason (2001)
Matono T, Tada T, Nishimura T, Takashima T, Aizawa N, Ikeda N, Shiomi H, Enomoto H, Iijima H.   +8 more
europepmc   +1 more source

10 POTENTIAL ENHANCEMENT OF BOTH EARLY (EVR) AND SUSTAINED (SVR) VIROLOGICAL RESPONSE BY FLUVASTATIN IN CHRONIC HEPATITIS C TREATED WITH STANDARD PEGIFN-RIBAVIRIN THERAPY. A PILOT STUDY

, 2011
E Georgescu, Liliana Streba, R Teodorescu, Garofiţa Olivia Mateescu, Mădălina Abagiu   +4 more
openalex   +1 more source

Donor–Recipient Epstein–Barr Virus Serostatus and Time‐Varying Risk of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients

Transplant Infectious Disease, EarlyView.
In a national US kidney transplant cohort, posttransplant lymphoproliferative disorder risk varied dynamically by donor–recipient Epstein–Barr virus serostatus. Donor‐positive/recipient‐negative recipients had the highest sustained risk, while donor‐negative/recipient‐negative recipients faced previously under‐recognized early risk, with PTLD strongly ...
Christie Rampersad, Seyed M. Hosseini‐Moghaddam, S. Joseph Kim   +2 more
wiley   +1 more source

Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.

Clinical Infectious Diseases, 2015
S. Kattakuzhy, E. Wilson, S. Sidharthan, Z. Sims, M. McLaughlin, A. Price, R. Silk, C. Gross, E. Akoth, Maryellen Mcmanus, B. Emmanuel, S. Shrivastava, Lydia Tang, Amy K. Nelson, Gebeyehu Teferi, J. Chavez, B. Lam, H. Mo, A. Osinusi, M. Polis, H. Masur, A. Kohli, S. Kottilil   +22 more
semanticscholar   +1 more source